Positive phase 2 data from Atrial Fibrillation clinical trial – primary endpoint met
First-in-class SK channel inhibition proof of mechanism achieved First new approach to treating Atrial Fibrillation for 20 years...
top of page
- May 5, 2020
- 2 min
Acesion Pharma Strengthens Clinical Team with Key Appointments
Acesion Pharma, a Danish pharmaceutical company developing novel treatments for atrial fibrillation (AF), the most common cardiac...
167 views
- Mar 12, 2019
- 2 min
Acesion Pharma receives 5M DKK from Innovation Fund Denmark to support human Proof-of-Concept study
Acesion Pharma (“Acesion” or the Company), a Danish biotech company developing novel treatments for atrial fibrillation (AF), the most...
57 views
LATEST NEWS
bottom of page